Targeting the senescence‒autophagy axis via p16INK4a inhibition alleviates pulmonary fibrosis [0.03%]
通过抑制p16INK4a作用于衰老-自噬轴可缓解肺纤维化
Young Jo Yoo,Mi Zhang,Seung-Hyun Jin et al.
Young Jo Yoo et al.
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease for which effective therapies are lacking. While cellular senescence and autophagy have been implicated in IPF pathogenesis, the intersecting mechanisms that drive ...
Liposomal doxorubicin plus nab-paclitaxel with/without chemoradiotherapy in head and neck adenoid cystic carcinoma: single-arm phase II study [0.03%]
载多柔比星脂质体结合纳米白蛋白紫杉醇联合/不联合同期放化疗治疗腺样囊性癌患者：单臂Ⅱ期临床研究
Xinxin Zhang,Jian Wei,Nanxiang Chen et al.
Xinxin Zhang et al.
Given no standard therapies, this single-arm, open-label, multicenter phase II study was conducted in unresectable locally advanced or recurrent/metastatic adenoid cystic carcinoma of the head and neck (LA or R/M ACCHN). Patients received c...
Anlotinib combined with neoadjuvant chemotherapy for HR+/HER2- breast cancer (ACNTBC): a prospective, single-arm, single-center phase II clinical study with real-world validation [0.03%]
阿帕替尼联合新辅助化疗治疗HR+/HER2-型乳腺癌（ACNTBC）：一项前瞻性、单臂、单中心II期临床试验及真实世界研究验证
Jiajun Ding,Huimin Meng,Yidi Wang et al.
Jiajun Ding et al.
Despite being an option for high-risk or inoperable cases, existing neoadjuvant therapies for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer yield suboptimal pathological responses, nec...
Wenjin Sun,Xuan Zhang,Ling Chen et al.
Wenjin Sun et al.
With rising global high-altitude travel, occupational exposure, and permanent habitation, the health burden of high-altitude-specific diseases and high-altitude-related diseases has become increasingly prominent, highlighting an urgent need...
Histaminylation alters collagen matrix mechanics and attenuates cardiac fibrosis post-myocardial infarction via mechanotransduction signaling axis [0.03%]
组胺基化通过机械转导信号轴改变胶原基质力学并在心肌梗死后减轻心脏纤维化
Jianfu Zhu,Dili Sun,Gaofeng Zeng et al.
Jianfu Zhu et al.
Histaminylation is a newly discovered monoaminylation catalyzed by transglutaminase 2 (TGM2), and its role in myocardial fibrosis has not yet been elucidated. Here, we identified histaminylation in cardiac type I collagen isolated from mice...
Unraveling the HGF/MET axis in Mallory-Denk body pathogenesis associated with liver fibrosis through single-cell transcriptomics [0.03%]
通过单细胞转录组学解开肝纤维化相关马洛里-登克体病理发生的HGF/MET轴机制
Xiaoping Tang,Yi Shi,Jia Pan et al.
Xiaoping Tang et al.
Mallory-Denk bodies (MDBs) are protein aggregates commonly observed in chronic liver diseases, including liver fibrosis. However, the intrahepatic crosstalk driving MDB pathogenesis and fibrosis progression remains poorly understood. Using ...
Targeting NFATc1-regulated MTHFD2 one-carbon metabolism to suppress sustained T-cell-mediated inflammation in rheumatoid arthritis [0.03%]
靶向NFATc1调节的MTHFD2一碳代谢以抑制类风湿关节炎中持续的T细胞介导炎症反应
Theodora Manolakou,Jianyu Shen,Sanjaykumar Boddul et al.
Theodora Manolakou et al.
T cells are central drivers of inflammation across autoimmune and inflammatory diseases, yet current therapies inadequately target pathogenic T-cell pathways, limiting durable disease control. Here, we identified a novel, targetable transcr...
Engineered tRNA reduces vision loss in a mouse model of Leber congenital amaurosis [0.03%]
工程化tRNA可减少Leber先天性黑蒙小鼠模型的视力丧失
Pawan K Shahi,Enes Akyuz,Lionel Gissot et al.
Pawan K Shahi et al.
Premature termination codons (PTCs) are a major class of pathogenic variants that underlie rare inherited disorders, including forms of childhood blindness. Therapeutic suppression of these "nonsense mutations" offers a gene- and position-a...
Efficacy and safety of toripalimab in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): a phase 1b/2 study [0.03%]
特瑞普利单抗联合西妥昔单抗治疗复发或转移性鼻咽癌（R/M NPC）的疗效和安全性：Ib/II期临床研究
Ye Guo,Zhendong Li,Liqiong Xue et al.
Ye Guo et al.
This open-label, multicenter, phase 1b/2 trial assessed the safety and efficacy of toripalimab plus cetuximab in patients with platinum-refractory (Cohort A) or previously untreated programmed cell death-ligand 1 (PD-L1)-positive (Cohort B)...